SMT202100373T1 - Metodi e composizioni per la stimolazione del sistema enteroendocrino intestinale per il trattamento di malattie o condizioni correlate allo stesso - Google Patents
Metodi e composizioni per la stimolazione del sistema enteroendocrino intestinale per il trattamento di malattie o condizioni correlate allo stessoInfo
- Publication number
- SMT202100373T1 SMT202100373T1 SM20210373T SMT202100373T SMT202100373T1 SM T202100373 T1 SMT202100373 T1 SM T202100373T1 SM 20210373 T SM20210373 T SM 20210373T SM T202100373 T SMT202100373 T SM T202100373T SM T202100373 T1 SMT202100373 T1 SM T202100373T1
- Authority
- SM
- San Marino
- Prior art keywords
- stimulation
- compositions
- methods
- same
- treating diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015657P | 2014-06-23 | 2014-06-23 | |
| US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| EP15811714.3A EP3157531B1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| PCT/US2015/036935 WO2015200195A1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202100373T1 true SMT202100373T1 (it) | 2021-07-12 |
Family
ID=54869043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20210373T SMT202100373T1 (it) | 2014-06-23 | 2015-06-22 | Metodi e composizioni per la stimolazione del sistema enteroendocrino intestinale per il trattamento di malattie o condizioni correlate allo stesso |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US10040817B2 (enExample) |
| EP (1) | EP3157531B1 (enExample) |
| JP (2) | JP6692300B2 (enExample) |
| CN (2) | CN106535902B (enExample) |
| BR (1) | BR112016029917A2 (enExample) |
| CA (1) | CA2951720C (enExample) |
| CY (1) | CY1124554T1 (enExample) |
| DK (1) | DK3157531T3 (enExample) |
| ES (1) | ES2878077T3 (enExample) |
| HR (1) | HRP20211005T1 (enExample) |
| HU (1) | HUE054828T2 (enExample) |
| LT (1) | LT3157531T (enExample) |
| MX (2) | MX382442B (enExample) |
| PL (1) | PL3157531T3 (enExample) |
| PT (1) | PT3157531T (enExample) |
| RS (1) | RS62064B1 (enExample) |
| SI (1) | SI3157531T1 (enExample) |
| SM (1) | SMT202100373T1 (enExample) |
| WO (1) | WO2015200195A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| WO2018222665A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating inflammatory diseases |
| WO2019050903A1 (en) * | 2017-09-08 | 2019-03-14 | Enterin Laboratories, Inc. | METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS |
| EP3704132A4 (en) * | 2017-10-30 | 2021-07-28 | Enterin, Inc. | NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM |
| AU2019242557A1 (en) * | 2018-03-27 | 2020-10-15 | Enterin, Inc. | Methods and compositions for treating hallucinations and conditions related to the same |
| WO2019241503A1 (en) * | 2018-06-13 | 2019-12-19 | Enterin, Inc. | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
| WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
| US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| WO2020028791A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| US20230125585A1 (en) * | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
| DE69412596T2 (de) | 1993-03-10 | 1999-03-04 | Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| WO1996008270A2 (en) | 1994-09-13 | 1996-03-21 | Magainin Pharmaceuticals Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
| US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| EP0832094B1 (en) | 1995-06-07 | 2004-02-11 | Genaera Corporation | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
| US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| PT910382E (pt) | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| CA2255856C (en) | 1996-05-17 | 2008-05-13 | Magainin Pharmaceuticals Inc. | Therapeutic uses for an aminosterol compound |
| WO1998019682A1 (en) | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
| JP2002522501A (ja) | 1998-08-12 | 2002-07-23 | ジェネーラ・コーポレーション | アミノステロール化合物類およびそれらの用途 |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| AU2002243204A1 (en) * | 2000-10-06 | 2002-06-11 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| WO2002032376A2 (en) | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| KR20100056569A (ko) * | 2002-01-28 | 2010-05-27 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료 방법 |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| EP2527355B1 (en) | 2005-04-25 | 2019-02-20 | Enterin, Inc. | Polymorphic and amorphous salt forms of squalamine dilactate |
| WO2009032321A2 (en) | 2007-09-06 | 2009-03-12 | Genaera Corporation | A method for treating diabetes |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| WO2011056650A2 (en) | 2009-10-27 | 2011-05-12 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| CA2870671C (en) | 2012-04-20 | 2020-05-12 | Ohr Pharmaceutical Inc. | Aminosteroids for the treatment of a ptp1b associated disease |
| CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
| US9504700B2 (en) | 2012-12-20 | 2016-11-29 | Mount Desert Island Biological Laboratory | Methods and compositions for stimulation and enhancement of regeneration of tissues |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 SM SM20210373T patent/SMT202100373T1/it unknown
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 MX MX2016017368A patent/MX382442B/es unknown
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en not_active Ceased
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| PL3349783T3 (pl) | Kompozycje i sposoby do leczenia chorób | |
| PT3157531T (pt) | Métodos e composições para estimulação do sistema enteroendócrino intestinal para tratamento de doenças ou condições relacionadas com o mesmo | |
| IL323562A (en) | Methods for treating inflammatory diseases | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| IL285003A (en) | Treatment of episode disorders | |
| IL257561A (en) | Methods for treating inflammatory diseases | |
| HUE055913T2 (hu) | Módszerek és készítmények a glioblastoma diagnosztizálására és kezelésére | |
| HUE059303T2 (hu) | Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| ZA201705877B (en) | Method of treating diseases | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
| IL253847A0 (en) | Methods of treating diseases | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| IL251135A0 (en) | A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases | |
| IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
| HK1236807A1 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases | |
| AP2016009662A0 (en) | Combination of taurine and racemethionine for treatment of liver diseases | |
| GB201516437D0 (en) | Compositions and methods relating to the treatment of disease | |
| AU2014904751A0 (en) | Methods for the treatment and prevention of asbestos-related diseases | |
| GB201414023D0 (en) | Treatment of autoimmune diseases |